Seattle PI -- Mirina, the microRNA drug developer at Accelerator, raised $3.9 million in its “expansion round” of financing that was reported earlier this week, according to a regulatory filing. The money ought to be enough to operate the company inside Accelerator for another 12-15 months as the company seeks to nail down more intellectual property around some advantages of its microRNA therapies, says Accelerator CEO Carl Weissman. Brian Atwood of Versant Ventures has joined the Mirina board, which also includes Weissman, Thong Le of WRF Capital, Steve Gillis of Arch Venture Partners, Chad Waite of OVP Venture Partners, Merl Hoekstra of Elitech Group, according to the filing.
